Foghorn Therapeutics Provides Updates On FHD-286 Development And Refocuses On Pipeline

Foghorn Therapeutics Inc., a clinical-stage biotech company focused on innovative treatments for diseases driven by abnormal gene expression, announced it will discontinue independent development of FHD-286 in combination with decitabine for patients with relapsed and/or refractory acute myeloid leukaemia (AML). The company is exploring partnerships and investigator-sponsored trials (ISTs) to advance FHD-286 further potentially.

Adrian Gottschalk, President and Chief Executive Officer of Foghorn, commented, “While clinical responses were observed for FHD-286, we will prioritise investment into our proprietary pipeline, including our Selective CBP program, Selective EP300 program, and ARID1B program, as well as our Lilly collaboration, including the clinical development of FHD-909. Our pipeline of potential medicines represents significant opportunities in oncology with the potential for therapeutic expansion. We want to thank the clinical investigators, the patients, and their families for participating in the FHD-286 clinical trial.”  

In the future, Foghorn will concentrate on its in-house initiatives and partnership with Lilly, such as the clinical-stage selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784). With $267.4 million in cash, cash equivalents, and marketable securities as of September 30, 2024, Foghorn has a financial runway through 2027.

The Phase 1 dose-escalation trial of FHD-286 in combination with decitabine showed objective clinical responses based on standard criteria. Still, the response rate did not meet the company’s threshold for independent continuation. Full trial results will be presented at a medical conference in 2025.